Protein Metabolism DisorderCANOLAANCT06058403
Impact of Canola Protein Processing on Plasma Amino Acid Responses
A study testing 20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion in people with Protein Metabolism Disorder, run by Maastricht University Medical Center at 1 site in Netherlands.
Trial summary
Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein through the diet, the body is provided with enough amino acids to facilitate muscle protein building. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Protein Metabolism Disorder
- What is being tested?
- 20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteNetherlands
- Study dates
- 3 Oct 2023to 27 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Female sex
- Aged between 18 and 35 y inclusive
- BMI between 18.5 and 30 kg/m2
Who cannot join
- Intolerant to milk lactose
- Allergic to milk protein / products
- Mustard allergy
- Vegan lifestyle
- Participating in a structured (progressive) exercise program
- Smoking regularly
Show all 16Show fewer
- Diagnosed GI tract disorders or diseases
- Diagnosed musculoskeletal disorders
- Diagnosed metabolic disorders (e.g., diabetes)
- Hypertension (blood pressure above 140/90 mmHg)
- Donated blood 2 months prior to test day
- Pregnant
- Using third generation oral contraceptives
- Use of any medications known to affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories).
- Chronic use of gastric acid suppressing medication as this impairs protein digestion (i.e., proton pump inhibitors, H2-antagonists)
- People with Phenylketonuria
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
Maastricht University Medical Centre+
Maastricht, Limburg, 6229ER
About this study
Official title: The Impact of Canola Protein Processing on Postprandial Plasma Amino Acid Responses in Vivo in Young Females
Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein through the diet, the body is provided with enough amino acids to facilitate muscle protein building. Providing the growing world population with sufficient animal-derived protein is a challenge. Plant proteins can be produced on a more sustainable commercial scale than conventional animal-derived proteins and therefore can contribute to feeding our future population. Canola protein is a protein that is derived from rapeseed. The composition of canola seems to be comparable to that of other high-quality animal based protein sources. However, the collection of canola protein from rapeseed occurs in a special way. These treatment processes might affect canola protein digestion. The goal of this study is to investigate the most optimal way of canola protein processing on blood plasma amino acid responses.
Primary objective: To assess the impact of canola protein processing on 5h postprandial plasma total amino acid incremental area under the curve (iAUC) in vivo in healthy young females.
Hypothesis: it is hypothesized that the ingestion of 20g processed canola will result in greater 5h postprandial plasma total amino acid iAUC in vivo in healthy young females, when compared to the ingestion of 20g native canola protein isolate.
Read the detailed description
To assess whether volunteers are eligible to participate in this study, the investigator will invite them to the University for a screening. At the start of the screening session, the entire experimental trial will be explained, and any potential questions will be answered. Thereafter, the volunteers are asked to read, fill out, and sign the informed consent form. After signing the informed consent form, the participant's eligibility will be assessed based on the in- and exclusion criteria. To further asses their eligibility, participants will be asked to fill out a medical questionnaire to assess their general health, use of medication, habitual food intake, and physical activity. Next, blood pressure will be assessed. Body mass (with accuracy of 0.1 kg) and height (with accuracy of 0.01 m) will be determined. The screening sessions will take place in the morning and participants are instructed to not have any breakfast in the morning in order to avoid perturbations in body weight and possibly in the DEXA scan. In the event of an unexpected medical finding during the screening, subjects will always be notified. If a subject does not want to receive this notification, she cannot participate in the study. When the screening is successfully performed, the test days will be scheduled. Protein and amino acid metabolism in women can be influenced by the menstrual cycle. Therefore, the experimental test days will be standardized in a specific period of the menstrual cycle. The test days will be planned in the first 10 days after the start of the menses (day 1 of the follicular phase), when hormones levels (i.e., estrogen) are low. In practice, this means that the test days will be planned based on the subjects' menstrual cycle. Therefore, 2 test days can be performed within 1 menstrual cycle (allowing 2 days between test days for standardization) and further test days will be planned approximately 28 days thereafter. This allows the investigators to finish testing for a single participant within a relatively short time frame while still taking the menstrual cycle and accompanying hormonal influences into consideration. A similar approach was used in our lab in previous studies that included young healthy women (METC17-3-047 \& METC19-087). Throughout the study period, participants will also undergo a fasted Dual Energy X-ray Absorptiometry (DEXA) scan to assess body composition. A DEXA scan is a simple, non-invasive procedure. At the beginning of the procedure, subjects will be asked to lie down on a scanning table wearing underwear and they need to remain motionless during the measurements. As the scanner moves, a dual energy beam passes through the targeted skeletal muscle section and is measured by a detector. This procedure takes approximately 3 minutes. The DEXA-scan provides valuable insight in participants' body composition, with minimal radiation burden.
When the screening is successfully performed, the test day will be scheduled. In order to prevent major impact from the menstrual cycle on the measurements of protein metabolism, the test day will be scheduled to take place in the first 10 days of the follicular phase.
Each subject will participate in 4 experimental test days lasting ~5h. Subjects will be instructed to arrive at the university at 8:45 AM in an overnight fasted and rested state, meaning that participants are not allowed to eat and drink (except for water) from 22:00 the night prior to the experimental trial. They will be instructed to come to the university by car or public transportation. After the subjects arrive at the University, subjects will rest in a seated position and a Teflon catheter will be inserted in a heated dorsal hand vein and placed in a hot-box (60°C) for arterialized blood sampling. A baseline blood sample (Serum + plasma = 20 mL) will be collected at t=0 min to determine the amino acid concentrations prior to the intervention.
Then, subjects will ingest the assigned drink (20g native canola protein, 20g processed canola protein #1, 20g processed canola protein #2, or 20g whey protein). Subjects will be instructed to consume the drink within ~5 min. Upon drink ingestion, the stopwatch will be started (t= 0 min), and arterialized blood samples (10mL) will be collected at t = 15, 30, 45, 60, 90, 120, 180, 240, and 300 min. During the entire experimental test day, the hand with the dorsal hand catheter will be pre-heated for 10 minutes prior to every blood draw in a hot box at 60°C to increase blood flow. This makes it easier to collect blood and minimizes nutrient exchange from blood into other tissues. Therefore, it allows the investigators to collect nutrient-rich (arterialized) blood from a vein.
In total 10 times blood samples will be taken during the test day, the first sample that will be collected will be 20mL and subsequent samples will be 10mL, making a total of 110mL.
Additionally, gastro-intestinal (GI) symptoms will be assessed at t = 0, 30, and 180 minutes and palatability at t = 15 min by questionnaires.
- Conditions
- Protein Metabolism Disorder
- Being tested
- 20g whey protein drink ingestion, 20g native canola protein drink ingestion, 20g processed canola protein #1 drink ingestion, 20g processed canola protein #2 drink ingestion
- Keywords
- Dietary protein, Plant protein, Protein processing, Protein digestion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
20g whey protein drink ingestionDietary supplement
Also called Supplement
Ingestion of a 300 mL drink containing 20g whey protein
20g native canola protein drink ingestionDietary supplement
Also called Supplement
Ingestion of a 300 mL drink containing 20g native canola protein
20g processed canola protein #1 drink ingestionDietary supplement
Also called Supplement
Ingestion of a 300 mL drink containing 20g processed canola protein #1
20g processed canola protein #2 drink ingestionDietary supplement
Also called Supplement
Ingestion of a 300 mL drink containing 20g processed canola protein #2
| Study group | Role | What they receive |
|---|---|---|
| Native canola protein | Experimental | 20g of canola protein Receives: Dietary Supplement: 20g native canola protein drink ingestion |
| Processed canola protein #1 | Experimental | 20g of processed canola #1 Receives: Dietary Supplement: 20g processed canola protein #1 drink ingestion |
| Processed canola protein #2 | Experimental | 20g of processed canola #2 Receives: Dietary Supplement: 20g processed canola protein #2 drink ingestion |
| Whey protein | Active comparator | 20g of whey protein Receives: Dietary Supplement: 20g whey protein drink ingestion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total amino acid availability
The total amino acid availability is expressed as the incremental area under the curve (iAUC)
Measured: 0 - 5 hours after drink ingestion
Secondary outcomes (7)
Postprandial plasma total amino acid concentrations
The total plasma amino acid concentrations from the sum of the individual amino acids
Measured: 0 - 5 hours after drink ingestion
Postprandial plasma individual amino acid concentrations
The plasma amino acid concentrations of the individual amino acids
Measured: 0 - 5 hours after drink ingestion
Peak plasma amino acid concentrations
The maximal plasma amino acid concentrations
Measured: 0 - 5 hours after drink ingestion
Time to peak plasma amino acid concentrations
The time to reach maximal plasma amino acid concentrations
Measured: 0 - 5 hours after drink ingestion
iAUC essential amino acids concentrations
Essential amino acid availability expressed as incremental area under the curve (iAUC)
Measured: 0 - 5 hours after drink ingestion
iAUC non-essential amino acid concentrations
non-essential amino acid availability expressed as incremental area under the curve (iAUC)
Measured: 0 - 5 hours after drink ingestion
Plasma insulin concentrations
Postprandial plasma insulin concentrations
Measured: 0 - 5 hours after drink ingestion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2023
- Study start3 Oct 2023
- Primary completion27 May 2024
- Study completion27 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Protein Metabolism DisorderStudies of the same condition, open and under way.
- More trials run by Maastricht University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, controlled, double-blind, cross-over intervention trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maastricht University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- DSM Food Specialties
- Responsible party
- Sponsor
- Investigators
- Luc van Loon, PhD, Principal investigator, Maastricht University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06058403
- Sponsor's protocol ID
- NL83369.068.23 / METC 23-025
- Acronym
- CANOLAA
- Status last verified
- Oct 2023
- First submitted
- 5 Sep 2023
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Boot N, Hermans WJH, Warnke I, Overman A, van Kranenburg JMX, Senden JM, Verdijk LB, van Loon LJC. Evaluation of processing of canola protein isolate on postprandial plasma amino acid profiles in healthy, young females. Amino Acids. 2025 Oct 17;57(1):50. doi: 10.1007/s00726-025-03482-1.
PubMed 41107640
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Canola Protein Processing on Postprandial Plasma Amino Acid Responses in Vivo in Young Females
- ClinicalTrials.gov ID
- NCT06058403
- Acronym / sponsor ID
- CANOLAA / NL83369.068.23 / METC 23-025
- Conditions
- Protein Metabolism Disorder
- Keywords
- Dietary protein, Plant protein, Protein processing, Protein digestion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Maastricht University Medical CenterUniversity, hospital or other
- Collaborators
- DSM Food Specialties
- Study start
- 3 Oct 2023 (actual)
- Primary completion
- 27 May 2024 (actual)
- Study completion
- 27 May 2024 (actual)
- First posted
- 28 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein through the diet, the body is provided with enough amino acids to facilitate muscle protein building. Providing the growing world population with sufficient animal-derived protein is a challenge. Plant proteins can be produced on a more sustainable commercial scale than conventional animal-derived proteins and therefore can contribute to feeding our future population. Canola protein is a protein that is derived from rapeseed. The composition of canola seems to be comparable to that of other high-quality animal based protein sources. However, the collection of canola protein from rapeseed occurs in a special way. These treatment processes might affect canola protein digestion. The goal of this study is to investigate the most optimal way of canola protein processing on blood plasma amino acid responses.
Primary objective: To assess the impact of canola protein processing on 5h postprandial plasma total amino acid incremental area under the curve (iAUC) in vivo in healthy young females.
Hypothesis: it is hypothesized that the ingestion of 20g processed canola will result in greater 5h postprandial plasma total amino acid iAUC in vivo in healthy young females, when compared to the ingestion of 20g native canola protein isolate.
Detailed description
To assess whether volunteers are eligible to participate in this study, the investigator will invite them to the University for a screening. At the start of the screening session, the entire experimental trial will be explained, and any potential questions will be answered. Thereafter, the volunteers are asked to read, fill out, and sign the informed consent form. After signing the informed consent form, the participant's eligibility will be assessed based on the in- and exclusion criteria. To further asses their eligibility, participants will be asked to fill out a medical questionnaire to assess their general health, use of medication, habitual food intake, and physical activity. Next, blood pressure will be assessed. Body mass (with accuracy of 0.1 kg) and height (with accuracy of 0.01 m) will be determined. The screening sessions will take place in the morning and participants are instructed to not have any breakfast in the morning in order to avoid perturbations in body weight and possibly in the DEXA scan. In the event of an unexpected medical finding during the screening, subjects will always be notified. If a subject does not want to receive this notification, she cannot participate in the study. When the screening is successfully performed, the test days will be scheduled. Protein and amino acid metabolism in women can be influenced by the menstrual cycle. Therefore, the experimental test days will be standardized in a specific period of the menstrual cycle. The test days will be planned in the first 10 days after the start of the menses (day 1 of the follicular phase), when hormones levels (i.e., estrogen) are low. In practice, this means that the test days will be planned based on the subjects' menstrual cycle. Therefore, 2 test days can be performed within 1 menstrual cycle (allowing 2 days between test days for standardization) and further test days will be planned approximately 28 days thereafter. This allows the investigators to finish testing for a single participant within a relatively short time frame while still taking the menstrual cycle and accompanying hormonal influences into consideration. A similar approach was used in our lab in previous studies that included young healthy women (METC17-3-047 \& METC19-087). Throughout the study period, participants will also undergo a fasted Dual Energy X-ray Absorptiometry (DEXA) scan to assess body composition. A DEXA scan is a simple, non-invasive procedure. At the beginning of the procedure, subjects will be asked to lie down on a scanning table wearing underwear and they need to remain motionless during the measurements. As the scanner moves, a dual energy beam passes through the targeted skeletal muscle section and is measured by a detector. This procedure takes approximately 3 minutes. The DEXA-scan provides valuable insight in participants' body composition, with minimal radiation burden.
When the screening is successfully performed, the test day will be scheduled. In order to prevent major impact from the menstrual cycle on the measurements of protein metabolism, the test day will be scheduled to take place in the first 10 days of the follicular phase.
Each subject will participate in 4 experimental test days lasting ~5h. Subjects will be instructed to arrive at the university at 8:45 AM in an overnight fasted and rested state, meaning that participants are not allowed to eat and drink (except for water) from 22:00 the night prior to the experimental trial. They will be instructed to come to the university by car or public transportation. After the subjects arrive at the University, subjects will rest in a seated position and a Teflon catheter will be inserted in a heated dorsal hand vein and placed in a hot-box (60°C) for arterialized blood sampling. A baseline blood sample (Serum + plasma = 20 mL) will be collected at t=0 min to determine the amino acid concentrations prior to the intervention.
Then, subjects will ingest the assigned drink (20g native canola protein, 20g processed canola protein #1, 20g processed canola protein #2, or 20g whey protein). Subjects will be instructed to consume the drink within ~5 min. Upon drink ingestion, the stopwatch will be started (t= 0 min), and arterialized blood samples (10mL) will be collected at t = 15, 30, 45, 60, 90, 120, 180, 240, and 300 min. During the entire experimental test day, the hand with the dorsal hand catheter will be pre-heated for 10 minutes prior to every blood draw in a hot box at 60°C to increase blood flow. This makes it easier to collect blood and minimizes nutrient exchange from blood into other tissues. Therefore, it allows the investigators to collect nutrient-rich (arterialized) blood from a vein.
In total 10 times blood samples will be taken during the test day, the first sample that will be collected will be 20mL and subsequent samples will be 10mL, making a total of 110mL.
Additionally, gastro-intestinal (GI) symptoms will be assessed at t = 0, 30, and 180 minutes and palatability at t = 15 min by questionnaires.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Randomized, controlled, double-blind, cross-over intervention trial
| Arm | Type | Receives |
|---|---|---|
| Native canola protein | Experimental | Dietary Supplement: 20g native canola protein drink ingestion20g of canola protein |
| Processed canola protein #1 | Experimental | Dietary Supplement: 20g processed canola protein #1 drink ingestion20g of processed canola #1 |
| Processed canola protein #2 | Experimental | Dietary Supplement: 20g processed canola protein #2 drink ingestion20g of processed canola #2 |
| Whey protein | Active comparator | Dietary Supplement: 20g whey protein drink ingestion20g of whey protein |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Female sex
- Aged between 18 and 35 y inclusive
- BMI between 18.5 and 30 kg/m2
Key exclusion criteria (16 listed)
- Intolerant to milk lactose
- Allergic to milk protein / products
- Mustard allergy
- Vegan lifestyle
- Participating in a structured (progressive) exercise program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 20g whey protein drink ingestionAlso: SupplementIngestion of a 300 mL drink containing 20g whey protein | Dietary supplement | Whey protein |
| 20g native canola protein drink ingestionAlso: SupplementIngestion of a 300 mL drink containing 20g native canola protein | Dietary supplement | Native canola protein |
| 20g processed canola protein #1 drink ingestionAlso: SupplementIngestion of a 300 mL drink containing 20g processed canola protein #1 | Dietary supplement | Processed canola protein #1 |
| 20g processed canola protein #2 drink ingestionAlso: SupplementIngestion of a 300 mL drink containing 20g processed canola protein #2 | Dietary supplement | Processed canola protein #2 |
Primary outcome
Total amino acid availability
Time frame: 0 - 5 hours after drink ingestion
The total amino acid availability is expressed as the incremental area under the curve (iAUC)
7 secondary outcomes
Postprandial plasma total amino acid concentrations
Time frame: 0 - 5 hours after drink ingestion
Postprandial plasma individual amino acid concentrations
Time frame: 0 - 5 hours after drink ingestion
Peak plasma amino acid concentrations
Time frame: 0 - 5 hours after drink ingestion
Time to peak plasma amino acid concentrations
Time frame: 0 - 5 hours after drink ingestion
iAUC essential amino acids concentrations
Time frame: 0 - 5 hours after drink ingestion
iAUC non-essential amino acid concentrations
Time frame: 0 - 5 hours after drink ingestion
Plasma insulin concentrations
Time frame: 0 - 5 hours after drink ingestion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Derived from this study: PubMed 41107640Boot N, Hermans WJH, Warnke I, Overman A, van Kranenburg JMX, Senden JM, Verdijk LB, van Loon LJC. Evaluation of processing of canola protein isolate on postprandial plasma amino acid profiles in healthy, young females. Amino Acids. 2025 Oct 17;57(1):50. doi: 10.1007/s00726-025-03482-1.
- Individual participant dataSharing planned: No
Related trials for Protein Metabolism Disorder
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Enrolling by invitationPhase 2
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
PSP - Progressive Supranuclear Palsy
Active, not recruitingPhase 2
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Multiple Myeloma, AL Amyloidosis
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luc van Loon, PhD principal investigator
Maastricht University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 20g whey protein drink ingestion, 20g native canola protein drink ingestion and 20g processed canola protein #1 drink ingestion in people with Protein Metabolism Disorder, run by Maastricht University Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total amino acid availability (time frame: 0 - 5 hours after drink ingestion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06058403, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.